EUVIMEDEUVIMED entdecken
Systematische ÜbersichtOpen Access · CC BY-NC-ND 4.0

Dupilumab for the Treatment of Cutaneous Immune‐Related Adverse Events: A Systematic Review

Ioannis-Alexios Koumprentziotis iD, Aikaterini Niforou, Antonios Tsimpidakis iD, Christos Nikolaou, Alexander Stratigos, Vasiliki Nikolaou iD

International Journal of Dermatology · 2025

DOI: 10.1111/ijd.17850 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift International Journal of Dermatology, 2025. Verfasst von Ioannis-Alexios Koumprentziotis und 5 weiteren Autor:innen. Beteiligte Einrichtung: First Department of Dermatology, "Andreas Sygros" Hospital for Skin Diseases, National and Kapodistrian University of Athens, Medical School, Athens,…. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Drug Eruptions, Immune Checkpoint Inhibitors. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The emergence of immune checkpoint inhibitors has revolutionized the landscape of cancer treatment in the modern era. However, cutaneous immune‐related adverse events (cirAEs) are common, significantly affecting patients' quality of life and often leading to treatment discontinuation, which may compromise oncological outcomes. Dupilumab, an immunoglobulin G4 (IgG4) human monoclonal antibody targeting interleukin (IL)‐4 and IL‐13 receptors, is widely used for dermatologic conditions but remains unapproved for cirAEs due to the limited and scattered supporting evidence. This review aimed to summarize the available evidence regarding the use of dupilumab for the management of cirAEs. A systematic review was conducted using MEDLINE/PubMed, Scopus, and Web of Science in adherence to the Preferred Reporting Items for Systematic Reviews and Meta‐Analyses (PRISMA) guidelines. In total, 25 publications met the eligibility criteria and were included, reporting 136 patients who were diagnosed with 140 cirAEs and were treated with dupilumab. The most frequently treated cirAEs were eczematous rashes, bullous pemphigoid, and maculopapular/morbilliform rashes. Dupilumab was found to be highly effective, with most patients achieving complete or partial responses, even when affected by two concomitant cirAEs. An acceptable safety profile was demonstrated regarding both adverse events and oncological safety, with no additional concerns to be raised. The findings may be encouraging but are limited by the relatively small number of patients treated and the nature of the included studies, with most of them being case reports and case series. More research is warranted, along with more clinical studies, prospective in design, focused on relevant clinical outcomes of this dupilumab‐treated subset of patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedDrug EruptionsImmune Checkpoint InhibitorsHumansExanthemaPemphigoid, Bullous

Stichwörter der Autor:innen

cancercutaneous immune related adverse eventdupilumabimmune checkpoint inhibitor

Substanzen

Antibodies, Monoclonal, HumanizeddupilumabImmune Checkpoint Inhibitors

Autor:innen und Institutionen

  • First Department of Dermatology, "Andreas Sygros" Hospital for Skin Diseases, National and Kapodistrian University of Athens, Medical School, Athens, Greece.
  • Department of Hygiene, Epidemiology and Medical Statistics, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.
  • Oncology Department, Queen's Hospital, London, UK.

ORCID-Profile: Ioannis-Alexios Koumprentziotis, Antonios Tsimpidakis, Vasiliki Nikolaou

Zitieren

APA

Koumprentziotis, I. A., Niforou, A., Tsimpidakis, A., Nikolaou, C., Stratigos, A., & Nikolaou, V. (2025). Dupilumab for the Treatment of Cutaneous Immune‐Related Adverse Events: A Systematic Review. International Journal of Dermatology. https://doi.org/10.1111/ijd.17850

Vancouver

Koumprentziotis IA, Niforou A, Tsimpidakis A, Nikolaou C, Stratigos A, Nikolaou V. Dupilumab for the Treatment of Cutaneous Immune‐Related Adverse Events: A Systematic Review. International Journal of Dermatology. 2025. doi:10.1111/ijd.17850

BibTeX
@article{Koumprentziotis2025,
  author = {Koumprentziotis, Ioannis-Alexios and Niforou, Aikaterini and Tsimpidakis, Antonios and Nikolaou, Christos and Stratigos, Alexander and Nikolaou, Vasiliki},
  title = {Dupilumab for the Treatment of Cutaneous Immune‐Related Adverse Events: A Systematic Review},
  journal = {International Journal of Dermatology},
  year = {2025},
  doi = {10.1111/ijd.17850}
}
Kostenlos starten →